By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia has received another clearance for the firm's MammaPrint breast cancer recurrence assay.

The new clearance is for running the test on two additional Agilent microarray scanners and two Agilent Bioanalyzers. Agendia said the additional clearance will expand laboratory capacity to handle the increasing number of MammaPrint, TargetPrint, and BluePrint test results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.